Lorglumide | CAS#97964-56-2 | CCKRA

MedKoo Cat#: 599237 | Name: Lorglumide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lorglumide is a highly effective competitive ligand for the cholecystokinine-A receptor (CCKRA).

Chemical Structure

Lorglumide

CAS#97964-56-2

Theoretical Analysis

MedKoo Cat#: 599237

Name: Lorglumide

CAS#: 97964-56-2

Chemical Formula: C22H32Cl2N2O4

Exact Mass: 458.1739

Molecular Weight: 459.40

Elemental Analysis: C, 57.52; H, 7.02; Cl, 15.43; N, 6.10; O, 13.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lorglumide; Lorglumidum;

IUPAC/Chemical Name

4-(3,4-dichlorobenzamido)-5-(dipentylamino)-5-oxopentanoic acid

InChi Key

IEKOTSCYBBDIJC-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)

SMILES Code

O=C(O)CCC(NC(C1=CC=C(Cl)C(Cl)=C1)=O)C(N(CCCCC)CCCCC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 459.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sturzu A, Sheikh S, Klose U, Echner H, Kalbacher H, Deeg M, Nägele T, Horger M, Schwentner C, Ernemann U, Heckl S. Potential of the gastric motility drug lorglumide in prostate cancer imaging. Eur J Pharm Sci. 2012 Apr 11;45(5):575-80. doi: 10.1016/j.ejps.2011.12.011. Epub 2011 Dec 30. PubMed PMID: 22226647. 2: Sharma K, Police A, Kumar A, Pawar GV, Giri S, Rajagopal S, Mullangi R. Development and validation of an LC-MS/MS-ESI method for the determination of lorglumide, a CCK-1 antagonist in mouse plasma: application to a pharmacokinetic study. Biomed Chromatogr. 2012 Jul;26(7):833-8. doi: 10.1002/bmc.1737. Epub 2011 Nov 3. PubMed PMID: 22052726. 3: Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. PubMed PMID: 3440035. 4: Sterczer A, Szénási G, Vörös K, Pap A. Effects of lorglumide and atropine on MgSO(4)-induced gallbladder emptying in conscious dogs. Res Vet Sci. 2000 Oct;69(2):129-33. PubMed PMID: 11020363. 5: Portincasa P, Brandonisio R, Di Ciaula A, Maggi V, Chiloiro M, Palasciano G. The effect of a novel CCK-antagonist (lorglumide) on human and guinea pig gallbladder strips: a tensiometric study. Boll Soc Ital Biol Sper. 1990 Jun;66(6):567-73. PubMed PMID: 2257123. 6: Wang SX. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats]. Zhongguo Yao Li Xue Bao. 1993 Sep;14(5):443-6. Chinese. PubMed PMID: 8010038. 7: van de Brug FJ, Jansen JB, Kuijpers IJ, Lamers CB. Effects of lorglumide on gastrin- and peptone-stimulated gastric acid secretion in rats. Life Sci. 1990;47(26):2459-64. PubMed PMID: 2263169. 8: Scarpignato C, Varga G, Dobronyi I, Papp M. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. Br J Pharmacol. 1989 Mar;96(3):661-9. PubMed PMID: 2470456; PubMed Central PMCID: PMC1854413. 9: Takács T, Nagy I, Pap A, Varró V. The effect of long-term administration of lorglumide (CR 1409) on rat pancreatic growth and enzyme composition. Pancreas. 1990 Sep;5(5):606-10. PubMed PMID: 1700417. 10: Zhou J, Zhang ZX, Li DC. Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway. Curr Ther Res Clin Exp. 2010 Aug;71(4):239-51. doi: 10.1016/j.curtheres.2010.08.005. PubMed PMID: 24688146; PubMed Central PMCID: PMC3969616. 11: Papp M, Varga G, Folly G. Effect of lorglumide (CR-1409) on pancreatic secretory and trophic response to caerulein in newborn rats. Acta Physiol Hung. 1991;78(1):61-7. PubMed PMID: 1722380. 12: Gaudreau P, Lavigne GJ, Quirion R. Cholecystokinin antagonists proglumide, lorglumide and benzotript, but not L-364,718, interact with brain opioid binding sites. Neuropeptides. 1990 May;16(1):51-5. PubMed PMID: 2174522. 13: Varga G, Papp M, Scarpignato C. Pancreatic secretory and trophic response to caerulein in rats: effect of proglumide and lorglumide. Fundam Clin Pharmacol. 1989;3(3):295-306. PubMed PMID: 2475419. 14: Makovec F, Bani M, Cereda R, Chistè R, Pacini MA, Revel L, Rovati LC. Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK. Pharmacol Res Commun. 1987 Jan;19(1):41-51. PubMed PMID: 3575382. 15: de Jong AJ, Singer MV, Jansen JB, Niebel W, Rovati LC, Lamers CB. Effect of the cholecystokinin-receptor antagonist lorglumide on pancreatic enzyme secretion stimulated by bombesin, food, and caerulein, giving similar plasma cholecystokinin concentrations in the dog. Gut. 1991 Feb;32(2):215-9. PubMed PMID: 1864545; PubMed Central PMCID: PMC1378812. 16: D'Amato M, Stamford IF, Bennett A. Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum. Br J Pharmacol. 1991 Feb;102(2):391-5. PubMed PMID: 2015421; PubMed Central PMCID: PMC1918051. 17: Meijers M, Appel MJ, van Garderen-Hoetmer A, Lamers CB, Rovati LC, Jansen JB, Woutersen RA. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide. Carcinogenesis. 1992 Sep;13(9):1525-8. PubMed PMID: 1394835. 18: Jiang LH, Kasser RJ, Wang RY. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons. Brain Res. 1988 Nov 8;473(1):165-8. PubMed PMID: 3208120. 19: van der Bent A, Blommaert AG, Melman CT, IJzerman AP, van Wijngaarden I, Soudijn W. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9. PubMed PMID: 1552499. 20: Watson SA, Morris DL, Durrant LG, Robertson JF, Hardcastle JD. Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide. Eur J Cancer. 1992;28A(8-9):1462-7. PubMed PMID: 1355350.